Company: MLTX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001821586-25-000018
Chunk: 4

Company: MoonLake Immunotherapeutics
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
 March 31, 202563,474,253 $6 729,320 $— $680,664 $(275,537)$2,387 $407,520 $5,061 $412,581 Share-based compensation under the ESPP and Equity Incentive Plan— $— — $— $3,298 $— $— $3,298 $11 $3,309 Net loss for the three months ended June 30, 2025— $— — $— $— $(55,220)$— $(55,220)$(831)$(56,051)Other comprehensive loss— $— — $— $— $— $(1,867)$(1,867)$(28)$(1,895)Balance at June 30, 202563,474,253 $6 729,320 $— $683,962 $(330,757)$520 $353,731 $4,213 $357,944 

The accompanying Notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.

5

MOONLAKE IMMUNOTHERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

Six Months Ended June 30, (in thousands)    20252024Cash flow from operating activitiesNet loss$(96,611)$(38,734)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization1,120670Share-based compensation expense5,5993,505Net periodic pension benefit gain for the qualified pension plan(9)(1)Other non-cash items(1,211)(113)Changes in operating assets and liabilities:Other receivables(566)(620)Operating lease right-of-use assets—(5)Prepaid expenses(3,570)(9,009)Other non-current assets(1,697)—Trade and other payables8,0873,305Operating lease liabilities(444)(723)Accrued expenses and other current liabilities(3,368)(1,113)Net cash flow used in operating activities(92,670)(42,838)Cash flow from investing activitiesPurchase of short-term marketable debt securities(206,207)(174,155)Proceeds from maturities of short-term marketable debt